OncoMatch/Clinical Trials/NCT06383780
Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.
Is NCT06383780 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including GP combined with Tislelizumab and TPC combined with Tislelizumab for nasopharyngeal carcinoma.
Treatment: GP combined with Tislelizumab · TPC combined with Tislelizumab — This is a prospective, open-label phase III clinical trial evaluating the efficacy and safety of the GP（Gemcitabine combined with cisplatin） regimen in combination with Tislelizumab versus the TPC（cisplatin, nab-paclitaxel and capecitabine）regimen in combination with Tislelizumab for the first-line treatment of Nasopharyngeal Carcinoma patients With Bone Metastasis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Hemoglobin > 8.0 g/dl; ANC > 1,500/mm3; Platelet count > 100,000/μl
Liver function
Total bilirubin ≤ 1.5x ULN; ALT and AST < 2.5x ULN (or < 5x ULN with liver metastases); alkaline phosphatase < 4x ULN; PT INR/PTT < 1.5x ULN
Good organ function:Hemoglobin > 8.0 g/dl; Absolute neutrophil count (ANC) >1,500/mm3; Platelet count> 100,000/μl; Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase and glutamate aminotransferase < 2.5 ULN (upper limit of normal), (alanine aminotransferase and aspartate aminotransferase < 5 ULN in patients with liver metastases), alkaline phosphatase< 4 ULN;Prothrombin time (PT) international normalized ratio/prothrombin time (PTT) < 1.5 ULN, serum muscle；Anhydride< 1.5ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06383780 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IVB is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages